Clinical trials: Mild to Moderate Hypertension
Hypertension
Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension
The purpose of this study is to evaluate the safety, efficacy, and tolerability of azilsartan medoxomil, once daily (QD), in individuals with hypertension.
- Trial name
- NCT00362115
- Testing
- Azilsartan Medoxomil, Olmesartan
- Where
- 54 sites in United States, Argentina and 2 more
- Volunteers
- 449 people
- Sponsor
- Takeda
Hypertension
Health Assessment Study (0954-946)
The study will look at the effects of losartan or atenolol on frequency of sexual intercourse in subjects with newly diagnosed mild to moderate hypertension.
- Trial name
- NCT00541684
- Testing
- MK0954, /Duration of Treatment : 16 Weeks, Comparator : atenolol /Duration of Treatment : 16 Weeks
- Volunteers
- 143 people
- Sponsor
- Organon and Co
Open Angle Glaucoma, Primary Open Angle Glaucoma
Safety and Effectiveness of the Hydrus Microstent
The purpose of this study is to assess the safety and effectiveness of the Hydrus Microstent for lowering intraocular pressure (IOP) in pseudophakic patients with open-angle glaucoma for whom IOP is not sufficiently controlled on…
- Conditions
- Open Angle Glaucoma, Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigmentary Glaucoma
- Trial name
- FRONTIER (NCT05198297)
- Testing
- Hydrus Microstent, Ophthalmic surgery
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- Alcon Research
Hypertension
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension
The purpose of this study is to evaluate the effect of ALN-AGT01 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of ALN-AGT01.
- Trial name
- KARDIA-1 (NCT04936035)
- Testing
- ALN-AGT01
- Where
- 75 sites in United States, Canada and 3 more
- Volunteers
- 394 people
- Sponsor
- Alnylam Pharmaceuticals
Essential Hypertension
Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension
The primary aim of the study is to assess the antihypertensive efficacy of SPH3127 in patients with mild to moderate essential hypertension.
- Trial name
- NCT05359068
- Testing
- SPH3127 tablet, Valsartan
- Where
- 40 sites in China
- Volunteers
- 957 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Chronic Kidney Disease, Hypertension
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), a progressive decrease in the kidneys' ability to work properly.
- Trial name
- NCT05491642
- Testing
- BAY3283142
- Where
- 4 sites in Bulgaria, Germany
- Volunteers
- 56 people
- Sponsor
- Bayer
Glaucoma, Ocular Hypertension
Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension
The goal of this clinical trial is to learn if two different doses of the SpyGlass Bimatoprost-Drug Ring System (BIM-DRS) work to treat adult pseudophakic patients with either glaucoma or ocular hypertension.
- Trial name
- NCT07641296
- Testing
- BIM-DRS Low Dose, BIM-DRS High Dose, SpyGlass IOL with silicone pads (no drug)
- Volunteers
- 24 people
- Sponsor
- SpyGlass Pharma, Inc.
Glaucoma, Open-Angle
A Prospective Evaluation of Glaucoma Subjects Treated With Two Second Generation iStents and One iStent Supra
Prospective Evaluation of Open-Angle Glaucoma Subjects treated with two second generation iStents and one iStent Supra
- Trial name
- GCF-041 (NCT03255798)
- Testing
- G2 and G3
- Where
- Germany
- Volunteers
- 7 people
- Sponsor
- Glaukos Corporation
Essential Hypertension
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
This study assessed the efficacy and safety of the valsartan/amlodipine 160/5 mg single-pill combination in patients with uncomplicated essential hypertension not adequately controlled (MSDBP ≥90 mmHg and <110 mmHg) on valsartan…
- Trial name
- NCT01001572
- Testing
- Valsartan/amlodipine 160/5 mg, Valsartan 160 mg
- Volunteers
- 932 people
- Sponsor
- Novartis
Hypertension
Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension
This is a study for people diagnosed with hypertension to compare the safety and effectiveness of aliskiren alone and in combination with atenolol. Each patient will be in the study for 12 weeks.
- Trial name
- NCT00262236
- Testing
- Aliskiren
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 693 people
- Sponsor
- Novartis
Hypertension
AVE7688 in Patients With Mild to Moderate Blood Pressure
The primary objective is to assess the antihypertensive efficacy of 4 different AVE 7688 doses on the change from baseline in trough diastolic blood pressure at the end of week 12.
- Trial name
- RAVEL-1 (NCT00284128)
- Testing
- AVE7688, Losartan-potassium
- Where
- 21 sites in United States, Argentina and 19 more
- Volunteers
- 1,940 people
- Sponsor
- Sanofi
Essential Hypertension
Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects
This is an 8-week, randomized, double-blind Phase 3, multicentre study to determine the optimal dose of AZM and AML in combination therapy and to compare efficacy and tolerability of the combined therapy to each of the…
- Trial name
- NCT05385770
- Testing
- AZM X mg + AML Y mg, AZM X mg + AML Y' mg, AZM X' mg + AML Y mg
- Where
- South Korea
- Volunteers
- 890 people
- Sponsor
- Celltrion
Hypertension
A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.
Valsartan, an orally active angiotensin II receptor blocker, is registered in most countries worldwide for the treatment of hypertension. In China the usual recommended starting and maintenance dose is 80 mg o.d.
- Trial name
- NCT00250562
- Testing
- valsartan plus hydrochlorothiazide
- Where
- United States
- Volunteers
- 1,171 people, healthy volunteers welcome
- Sponsor
- Novartis
Essential Hypertension
Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension
Aim of this study is to compare the blood pressure lowering effect of a new drug formulation of eprosartan. Eprosartan belongs to a class of blood pressure lowering agents used worldwide since years with proven efficacy.
- Trial name
- NCT01631227
- Testing
- Eprosartan, Eprosartan Mesylate
- Where
- 38 sites in Germany, Russia and 1 more
- Volunteers
- 665 people
- Sponsor
- Abbott
Symptomatic Neurogenic Orthostatic Hypertension, nOH
Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855
An open-label study to characterize the effects of mild, moderate, and severe Hepatic Impairment (HI) on the pharmacokinetics (PK) of ampreloxetine following a single oral dose in comparison with healthy volunteers with normal…
- Trial name
- NCT04200573
- Testing
- Ampreloxetine
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Hypertension
Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring
The primary aim of the trial is to compare telmisartan 80 mg to valsartan 160 mg in lowering diastolic blood pressure in patients who missed a dose of their medication, as measured by ABPM (change from baseline in mean DBP over…
- Trial name
- NCT02242318
- Testing
- Telmisartan, Valsartan
- Volunteers
- 440 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Tadalafil in Subjects With Mild to Moderate Hypertension
Purpose: The primary objective of this study is to evaluate the efficacy and safety of tadalafil when administered once daily at doses of 5 and 20 mg to adult subjects for 8 weeks with mild to moderate hypertension.
- Trial name
- NCT00157326
- Testing
- tadalafil
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Eli Lilly and Company
Hypertension
VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis
The purpose of the study is to compare the efficacy, safety and tolerability of valsartan 80 mg (with a starting dose of 40 mg) to irbesartan 150 mg (with a starting dose of 75 mg) in patients on long-term haemodialysis with mild…
- Trial name
- NCT00171080
- Testing
- valsartan, irbesartan
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 86 people
- Sponsor
- Novartis
Cataract, Ocular Hypertension
Evaluation of the Safety and Effectiveness of the Bimatoprost Implant System / IOL Combination in Patients With Ocular Hypertension or Mild to Moderate Open-angle Glaucoma
The goal of this clinical trial is to learn if the SpyGlass Pharma Bimatoprost Implant System / IOL Combination works to treat cataracts and either ocular hypertension or glaucoma.
- Conditions
- Cataract, Ocular Hypertension, Glaucoma
- Trial name
- NCT07154797
- Testing
- Bimatoprost Implant System / IOL Combination
- Where
- Honduras
- Volunteers
- 24 people
- Sponsor
- SpyGlass Pharma, Inc.
Hypertension
Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.
To evaluate efficacy and safety of valsartan 160mg in Chinese hypertensive patients.
- Trial name
- NCT01541189
- Testing
- Valsartan
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals